Table 3 Multivariable Cox regression analysis for overall survival of AML patients.

From: SOCS2 is part of a highly prognostic 4-gene signature in AML and promotes disease aggressiveness

Data set/cohort

Variable

4-GES

L-24

M-7

W-3

HR

95% CI

p-value

HR

95% CI

p-value

HR

95% CI

p-value

HR

95% CI

p-value

GSE12417/1

GE score, high vs. low

3.8

2.3–6.2

8.8 * 10−08

2.25

1.5–3.4

7.5 * 10−05

na

Na

na

1.51

1.07–2.14

0.021

Age (years)

1.02

1.0–1.0

0.006

1.03

1.0–1.04

0.0003

na

Na

na

1.03

1.01–1.04

0.0004

GSE12417/2

GE score, high vs. low

4.58

1.1–18.9

0.035

ns

ns

ns

2.68

1.5–4.9

0.0016

2.01

1.1–3.7

0.022

Age (years)

1.04

1.0–1.1

0.008

ns

ns

ns

1.03

1.0–1.06

0.0063

1.03

1.0–1.1

0.0079

GSE6891/1

GE score, high vs. low

1.69

1.2–2.5

0.008

1.1

0.8–1.6

0.56

2.0

1.4–2.8

5.3 * 10−05

ns

ns

ns

Cytogenetic riska

1.91

1.5–2.5

1.4 * 10−06

1.97

1.5–2.6

3.7 * 10−07

1.98

1.6–2.5

2.9 * 10−08

ns

ns

ns

CEBPAm (w/m/b)

0.79

0.1–6.4

0.828

0.84

0.1–8.1

0.878

0.95

0.1–6.4

0.957

ns

ns

ns

CEBPAm (yes/no)

0.94

0.0–57.1

0.976

0.71

0.0–61.2

0.878

0.66

0.01–27.5

0.83

ns

ns

ns

EVI1 expression (+/−)

0.82

0.5–1.5

0.511

0.95

0.5–1.7

0.854

0.89

0.5–1.6

0.681

ns

ns

ns

FLT3-ITD

1.38

0.9–2.0

0.106

1.69

1.2–2.5

0.006

1.82

1.3–2.6

0.0008

ns

ns

ns

GSE6891/2

GE score, high vs. low

2.24

1.5–3.4

0.0001

1.33

0.9–2.0

0.173

1.7

1.1–2.5

0.0086

ns

ns

ns

Age (years)

1.01

1.0–1.03

0.281

1.01

1.0–1.03

0.128

1.01

1.0–1.03

0.102

ns

ns

ns

Cytogenetic riska

1.13

0.8–1.6

0.528

1.22

0.9–1.75

0.27

1.35

1.0–1.92

0.092

ns

ns

ns

EVI1 expression (+/−)

3.73

1.8–7.6

0.0002

2.95

1.5–6.0

0.0025

2.9

1.4–5.8

0.0028

ns

ns

ns

GSE37642

GE score, high vs. low

2.13

1.6–2.8

1.8 * 10−07

1.49

1.2–1.9

0.0016

na

Na

na

ns

ns

ns

Age (years)

1.03

1.0–1.04

5.6 * 10−12

1.03

1.0–1.04

1.5 * 10−13

na

Na

na

ns

ns

ns

ELN scoreb

1.26

1.1–1.4

7.1 * 10−05

1.33

1.2–1.5

4.1 * 10−07

na

Na

na

ns

ns

ns

FAB, M1 vs. others

1.06

0.8–1.4

0.718

0.95

0.7–1.3

0.745

na

Na

na

ns

ns

ns

FAB, M4 vs. others

1.32

1.0–1.8

0.074

1.45

1.1–2.0

0.017

na

Na

na

ns

ns

ns

TCGA_LAML

GE score, high vs. low

1.52

1.0–2.3

0.051

1.3

0.8–2.1

0.249

ns

Ns

ns

2.45

1.4–4.3

0.002

Age (years)

1.03

1.0–1.1

0.00013

1.03

1.0–1.1

8.8 * 10−05

ns

Ns

ns

1.04

1.0–1.1

2.3 * 10−05

Cytogenetic riska

1.29

0.9–1.9

0.179

1.25

0.8–1.9

0.265

ns

Ns

ns

1.49

1.0–2.1

0.033

  1. Parameters provided with the respective data sets were first tested in univariable analyses (Supplementary Table S1); those that resulted as significant were included in the multivariable models, whose results are summarized in this table. 4-GES, 4-gene expression score; L-24, 24-gene expression signature by Li et al.16; M-7, 7-gene expression signature by Marcucci et al.19; W-3, 3-gene expression signature by Wilop et al.20; HR, hazard ratio; CI, confidence interval; GE score, gene expression score; CEBPAm, CEBPA mutation; w, wild type; m, monoallelic; b, biallelic. aAssignment to cytogenetic risk groups were included in the respective GEO entries. bAssignment to ELN risk groups was provided by T. Herold, University of Munich, Department of Internal Medicine III, Munich, Germany. No relevant patient data were provided in GSE71014; therefore, multivariable analyses could not be performed. Significant p-values and corresponding HRs and Cis are indicated in bold letters. na, score could not be calculated because 2 signature genes were not represented on HG-U133A microarrays; ns, no statistical significance found in univariable analyses, thus, no multivariable analyses were performed.
Back to article page